BioCentury
ARTICLE | Company News

Biogen, AGTC partner in ophthalmic gene therapy

July 3, 2015 1:09 AM UTC

Biogen Inc. (NASDAQ:BIIB) and Applied Genetic Technologies Corp. (NASDAQ:AGTC) partnered to develop and commercialize gene therapies for ophthalmic diseases. AGTC will receive $124 million up front and is eligible for $1.1 billion in milestones.

Biogen will gain exclusive, worldwide rights to rAAV2tYF-CB-hRS1 to treat X-linked retinoschisis ( XLRS) and a preclinical candidate to treat X-linked retinitis pigmentosa (XLRP). Biogen has no other ophthalmic candidates. ...